An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer, Endocrine |
| Therapuetic Areas: | Endocrinology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/6/2019 |
| Start Date: | April 8, 2015 |
| End Date: | July 31, 2020 |
RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
The purpose of the study is to assess the use of Multikinase Inhibitors (MKIs) in the
treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to
radioactive iodine (RAI) who do not have any symptoms.
treatment of patients with a progressive differentiated thyroid carcinoma (DTC) refractory to
radioactive iodine (RAI) who do not have any symptoms.
The primary objective of this study is to compare time to symptomatic progression (TTSP) from
study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a
decision to initiate MKIs at study entry with that of asymptomatic patients with
RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study
entry.
study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a
decision to initiate MKIs at study entry with that of asymptomatic patients with
RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study
entry.
Inclusion Criteria:
- Histologically/cytologically documented DTC (papillary, follicular, Hurthle cell, and
poorly differentiated carcinoma)
- DTC refractory to RAI
- Radiological progression and preferably according to RECIST 1.1
- No symptoms due to DTC
- >/=1cm diameter of lesion confirmed by radiological exam
- Life expectancy of at least 6 months
Exclusion Criteria:
- Plan to be treated according to a clinical trial protocol for intervention including a
locoregional therapy or systemic therapy
- Previous treatment with MKIs for advanced disease
- Hospice patients
We found this trial at
18
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials